Laboratory of Molecular and Cellular Cardiology, Cardiovascular Institute, Magna Graecia University, URT-National Research Council, Catanzaro, Italy.
Basic Res Cardiol. 2012 Sep;107(5):296. doi: 10.1007/s00395-012-0296-y. Epub 2012 Aug 14.
The role of miR-92a on vascular remodelling after injury is currently unknown. Thus, the aim of the present study was to evaluate the role of miR-92a on rat endothelial and vascular smooth muscle cells proliferation and migration in vitro as well as after balloon injury or arterial stenting in vivo. MiR-92a was highly expressed in RAO-ECs and vascular endothelium, but not in RAO-SMCs or medial smooth muscle as assessed by real-time RT-PCR. Importantly, BrdU incorporation and wound healing assay provide evidence that functional inhibition of miR-92a resulted in an increased RAO-ECs proliferation and migration, but had no effect on RAO-SMCs proliferation or migration in vitro. Immunoblotting analysis revealed an increased phosphorylation of ERK1/2, JNK/SAPK as well as eNOS and phospho-eNOS increased expression level in RAO-ECs as a consequence of miR-92a inhibition. Using gain and loss of function experiments, we showed that miR-92a modulates regulation of KLF4 and MKK4 expression level in endothelial cells. Finally, in vivo administration of antagomiR-92a significantly enhanced re-endothelialization in injured carotid arteries and reduced neointimal formation after balloon injury or arterial stenting. These data provide the first evidence that inhibition of miR-92a may represent a novel strategy to improve endothelial regeneration and reduce restenosis after vascular injury.
miR-92a 在损伤后血管重构中的作用目前尚不清楚。因此,本研究旨在评估 miR-92a 在体外大鼠内皮细胞和血管平滑肌细胞增殖和迁移中的作用,以及在体内球囊损伤或动脉支架置入后的作用。实时 RT-PCR 评估表明,miR-92a 在 RAO-ECs 和血管内皮中高表达,但在 RAO-SMCs 或中膜平滑肌中不表达。重要的是,BrdU 掺入和划痕愈合试验提供的证据表明,miR-92a 的功能抑制导致 RAO-ECs 增殖和迁移增加,但对 RAO-SMCs 的增殖或迁移没有影响。免疫印迹分析显示,miR-92a 抑制导致 RAO-ECs 中 ERK1/2、JNK/SAPK 以及 eNOS 和磷酸化 eNOS 的表达水平增加。通过增益和失活实验,我们表明 miR-92a 调节内皮细胞中 KLF4 和 MKK4 表达水平。最后,体内给予 antagomiR-92a 可显著增强损伤颈动脉的再内皮化,并减少球囊损伤或动脉支架置入后的新生内膜形成。这些数据首次表明,抑制 miR-92a 可能代表一种改善血管损伤后内皮再生和减少再狭窄的新策略。